CEO and Managing Director Matthew Liddelow discusses how NeuroScienfitic is revolutionising the treatment of Alzheimer’s disease and optic nerve conditions through its lead drug candidate, called EmtinB. Providing insights into the Company's exciting developments and global collaborations, Matthew shares the successfully results achieved through preclinical trials and the plans to start clinical trails by the end of 2020.

NeuroScienfitic Biopharmaceuticals Ltd (NSB.ASX) is a drug development company focused on developing novel peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.

Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.

Accurate time of recording, 10 June 2020 at 12pm AEST.